A Glimpse Into The Expert Outlook On AnaptysBio Through 6 Analysts
AnaptysBio Is Maintained at Buy by Guggenheim
Express News | AnaptysBio Inc : Guggenheim Raises Target Price to $90 From $75
Leerink Partners Maintains AnaptysBio(ANAB.US) With Buy Rating
"Buy" Rating for AnaptysBio Driven by Promising Preclinical Data on Rosnilimab's Ulcerative Colitis Treatment Potential
Analysts Offer Insights on Healthcare Companies: Edgewise Therapeutics (EWTX) and AnaptysBio (ANAB)
AnaptysBio Insiders Sell US$3.6m Of Stock, Possibly Signalling Caution
Piper Sandler Maintains AnaptysBio(ANAB.US) With Buy Rating, Maintains Target Price $80
12 Health Care Stocks Moving In Monday's Pre-Market Session
Wedbush Maintains AnaptysBio(ANAB.US) With Buy Rating, Maintains Target Price $42
J.P. Morgan Maintains AnaptysBio(ANAB.US) With Buy Rating
J.P. Morgan Reaffirms Their Buy Rating on AnaptysBio (ANAB)
AnaptysBio Chief Legal Officer Sells Over $490k in Company Stock
BTIG Initiates AnaptysBio(ANAB.US) With Buy Rating, Announces Target Price $55
BTIG analyst Jake Fuller initiates coverage on $AnaptysBio(ANAB.US)$ with a buy rating, and sets the target price at $55.According to TipRanks data, the analyst has a success rate of 48.1% and a
Anaptys Announces Participation in September Investor Conferences
Why AnaptysBio Was Such a Healthy Stock This Week
Small-cap and Mid-cap Health Care Has Room to Rally - Roth MKM
Insiders Buying Yum China And 2 Other Stocks
AnaptysBio(ANAB.US) 10% Shareholder Buys US$10 Million in Common Stock
$AnaptysBio(ANAB.US)$ 10% Shareholder EcoR1 Capital, LLC purchased 273.97K shares of common stock on Aug 14, 2024 at an average price of $36.5 for a total value of $10 million.Source: Announcement
AnaptysBio Price Target Raised to $30.00/Share From $20.00 by Truist Securities